

Amendments to the Specification:

Page 1, before line 1, insert:

Cross Reference to Related Application

This application is a 35 USC § 371 National Phase Entry Application from PCT/CA2003/001335, filed September 2, 2003, and designating the United States, which claims the benefit of U.S. Provisional 60/407,242, filed September 3, 2002.

Please replace paragraph [0005] with the following amended paragraph:

[0005] In US Patents Nos. 6,288,799 6,284,799, 5,859,065, 5,708,329 5,798,339, 5,747,543 and 5,618,846, all assigned to University of Manitoba and the disclosures of which are incorporated herein by reference, there is described an improved method for the *in vivo* chemotherapeutic treatment of cancer in which there is first administered a compound which inhibits normal cell proliferation while promoting malignant cell proliferation, specifically a potent antagonist selective for intracellular histamine receptors, in an amount sufficient to inhibit the binding of intracellular histamine to the receptors in normal and malignant cells. Following sufficient time to permit the inhibition of binding of intracellular histamine, a chemotherapeutic agent is administered. An enhanced toxic effect on the cancer cells from the chemotherapeutic agent is obtained while any adverse effect of the chemotherapeutic agent on normal cells, particularly bone marrow and gastro-intestinal cells, is significantly ameliorated. One useful compound which inhibits normal cell proliferation while promoting malignant cell proliferation is N,N-diethyl-2-[4-(phenylmethyl)-phenoxy]ethanamine, abbreviation herein as DPPE.